{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:34Z","timestamp":1792242334639,"version":"4.4.0"},"reference-count":41,"publisher":"Hindawi Limited","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":348,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1111\/ijcp.12568","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T08:01:09Z","timestamp":1411027269000},"page":"1429-1441","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?"],"prefix":"10.1155","volume":"68","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[{"name":"New York Medical College; Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"10.1111\/ijcp.12568-BIB0001|ijcp12568-cit-0001","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ncl.2012.08.012","article-title":"Insomnia","volume":"30","author":"Deak","year":"2012","journal-title":"Neurol Clin"},{"key":"10.1111\/ijcp.12568-BIB0002|ijcp12568-cit-0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"Ohayon","year":"2002","journal-title":"Sleep Med Rev"},{"key":"10.1111\/ijcp.12568-BIB0003|ijcp12568-cit-0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/sleep\/30.2.213","article-title":"Comorbidity of chronic insomnia with medical problems","volume":"30","author":"Taylor","year":"2007","journal-title":"Sleep"},{"key":"10.1111\/ijcp.12568-BIB0004|ijcp12568-cit-0004","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5"},{"key":"10.1111\/ijcp.12568-BIB0005|ijcp12568-cit-0005","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/sleep\/28.11.1457","article-title":"Epidemiology of insomnia, depression, and anxiety","volume":"28","author":"Taylor","year":"2005","journal-title":"Sleep"},{"key":"10.1111\/ijcp.12568-BIB0006|ijcp12568-cit-0006","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/09540261.2014.888990","article-title":"New and emerging pharmacotherapeutic approaches for insomnia","volume":"26","author":"Neubauer","year":"2014","journal-title":"Int Rev Psychiatry"},{"issue":"Suppl 1","key":"10.1111\/ijcp.12568-BIB0007|ijcp12568-cit-0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.13011su1c","article-title":"Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system","volume":"74","author":"Krystal","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12568-BIB0008|ijcp12568-cit-0008","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.tips.2006.05.006","article-title":"The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions","volume":"27","author":"Zeitzer","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/ijcp.12568-BIB0009|ijcp12568-cit-0009","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrd4067","article-title":"First-in-class insomnia drug on the brink of approval nod","volume":"12","author":"Osborne","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/ijcp.12568-BIB0010|ijcp12568-cit-0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14728214.2012.693158","article-title":"Update on emerging drugs for insomnia","volume":"17","author":"Sullivan","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1111\/ijcp.12568-BIB0011|ijcp12568-cit-0011","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cmdc.201000132","article-title":"Orexin receptor antagonists: a new concept in CNS disorders?","volume":"5","author":"Gatfield","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1111\/ijcp.12568-BIB0012|ijcp12568-cit-0012","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia","volume":"171","author":"Winrow","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1111\/ijcp.12568-BIB0013|ijcp12568-cit-0013","unstructured":"US Food and Drug Administration NDA approval letter 2014 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/204569Orig1s000rltr.pdf"},{"key":"10.1111\/ijcp.12568-BIB0014|ijcp12568-cit-0014","unstructured":"Merck Sharp & Dohme Corporation BELSOMRA (suvorexant) tablets, for oral use 2014 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204569s000lbledt.pdf"},{"key":"10.1111\/ijcp.12568-BIB0015|ijcp12568-cit-0015","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem"},{"key":"10.1111\/ijcp.12568-BIB0016|ijcp12568-cit-0016","unstructured":"Drug Enforcement Administration, Department of Justice Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule Fed Regis 2014 79 51243 7"},{"key":"10.1111\/ijcp.12568-BIB0017|ijcp12568-cit-0017","unstructured":"US Food and Drug Administration Suvorexant (orexin receptor antagonist) briefing materials 2013 http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM352969.pdf"},{"key":"10.1111\/ijcp.12568-BIB0018|ijcp12568-cit-0018","unstructured":"Merck Sharp & Dohme Corporation Suvorexant advisory committee meeting briefing document 2013 http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/peripheralandcentralnervoussystemdrugsadvisorycommittee\/ucm352970.pdf"},{"key":"10.1111\/ijcp.12568-BIB0019|ijcp12568-cit-0019","unstructured":"Merck Sharp & Dohme Corporation Suvorexant advisory committee meeting briefing document addendum 2013 http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/peripheralandcentralnervoussystemdrugsadvisorycommittee\/ucm352971.pdf"},{"key":"10.1111\/ijcp.12568-BIB0020|ijcp12568-cit-0020","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ijcp.12568-BIB0021|ijcp12568-cit-0021","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1111\/ijcp.12568-BIB0022|ijcp12568-cit-0022","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"key":"10.1111\/ijcp.12568-BIB0023|ijcp12568-cit-0023","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.12568-BIB0024|ijcp12568-cit-0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.12568-BIB0025|ijcp12568-cit-0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12568-BIB0026|ijcp12568-cit-0026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"10.1111\/ijcp.12568-BIB0027|ijcp12568-cit-0027","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"J Expert Rev Neurother"},{"key":"10.1111\/ijcp.12568-BIB0028|ijcp12568-cit-0028","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40263-012-0036-8","article-title":"Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status","volume":"27","author":"Mieda","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12568-BIB0029|ijcp12568-cit-0029","first-page":"264","article-title":"Suvorexant, a dual orexin receptor antagonist for the management of insomnia","volume":"39","author":"Bennett","year":"2014","journal-title":"P T"},{"key":"10.1111\/ijcp.12568-BIB0030|ijcp12568-cit-0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00023210-200418050-00003","article-title":"Residual effects of hypnotics: epidemiology and clinical implications","volume":"18","author":"Vermeeren","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12568-BIB0031|ijcp12568-cit-0031","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11606-007-0251-z","article-title":"The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs","volume":"22","author":"Buscemi","year":"2007","journal-title":"J Gen Intern Med"},{"key":"10.1111\/ijcp.12568-BIB0032|ijcp12568-cit-0032","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","article-title":"Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits","volume":"331","author":"Glass","year":"2005","journal-title":"BMJ"},{"key":"10.1111\/ijcp.12568-BIB0033|ijcp12568-cit-0033","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/hup.594","article-title":"Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis","volume":"19","author":"D\u00fcndar","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1111\/ijcp.12568-BIB0034|ijcp12568-cit-0034","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp.159.1.5","article-title":"Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia","volume":"159","author":"Smith","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12568-BIB0035|ijcp12568-cit-0035","first-page":"225","article-title":"Meta-analysis of benzodiazepine use in the treatment of insomnia","volume":"162","author":"Holbrook","year":"2000","journal-title":"CMAJ"},{"key":"10.1111\/ijcp.12568-BIB0036|ijcp12568-cit-0036","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1001\/jama.1997.03550240060035","article-title":"Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy","volume":"278","author":"Nowell","year":"1997","journal-title":"JAMA"},{"key":"10.1111\/ijcp.12568-BIB0037|ijcp12568-cit-0037","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1742-1241.2012.02987.x","article-title":"Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis","volume":"66","author":"Liu","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12568-BIB0038|ijcp12568-cit-0038","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/15389588.2013.830211","article-title":"Meta-analysis of on-the-road experimental studies of hypnotics: effects of time after intake, dose, and half-life","volume":"15","author":"Roth","year":"2014","journal-title":"Traffic Inj Prev"},{"key":"10.1111\/ijcp.12568-BIB0039|ijcp12568-cit-0039","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1474-4422(13)70311-9","article-title":"Orexin receptor antagonists: a new treatment for insomnia?","volume":"13","author":"Riemann","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1111\/ijcp.12568-BIB0040|ijcp12568-cit-0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40263-014-0198-7","article-title":"Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials","volume":"28","author":"Winkler","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12568-BIB0041|ijcp12568-cit-0041","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.2013.193","article-title":"Insomnia","volume":"309","author":"Buysse","year":"2013","journal-title":"JAMA"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12568","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:08:48Z","timestamp":1643350128000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12568","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9,18]]},"assertion":[{"value":"2014-07-16","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}